Expanding the Patient Pool for Rilonacept.

Area of Science:

• Cardiology
• Immunology
• Pharmacology

Background:

• Recurrent pericarditis is a common complication of acute pericarditis, affecting 15%-30% of cases.
• Standard anti-inflammatory treatments are often insufficient for preventing pericarditis recurrence.
• Interleukin-1 (IL-1) pathway dysregulation is implicated in the pathogenesis of recurrent pericarditis.

Observation:

• The RHAPSODY trial demonstrated the efficacy of rilonacept, an IL-1 cytokine trap, in treating recurrent pericarditis.
• This case series explores the real-world application of rilonacept in patients with recurrent pericarditis.
• Patients included in this series had characteristics that excluded them from the RHAPSODY trial, representing a broader clinical population.

Findings:

• Rilonacept demonstrated utility in managing recurrent pericarditis in a diverse patient group.
• The use of rilonacept in this case series highlighted both its effectiveness and potential challenges in clinical practice.
• Specific challenges and successful management strategies for rilonacept in complex recurrent pericarditis cases were observed.

Implications:

• Rilonacept represents a valuable therapeutic option for recurrent pericarditis, extending beyond trial participants.
• Understanding the utility and challenges of rilonacept in real-world settings can optimize patient care.
• Further research into IL-1 inhibition for pericarditis may lead to improved treatment paradigms for refractory cases.